R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats

Area of Science:

• Neuroscience
• Sleep Medicine
• Pharmacology

Background:

• Central apneas disrupt sleep architecture and respiratory patterns.
• Serotonin receptors (5-HT3 and 5-HT4) are implicated in respiratory control.
• R-zacopride is a benzamide with known 5-HT3 antagonist and 5-HT4 agonist properties.

Purpose of the Study:

• To investigate the efficacy of R-zacopride in suppressing spontaneous central apneas in a rat model.
• To evaluate the dose-dependent effects of R-zacopride on respiratory and sleep patterns.

Main Methods:

• 10 Sprague-Dawley rats were administered R-zacopride at doses of 0.5, 1.0, and 10.0 mg/kg.
• Respiration and sleep were monitored for 6 hours post-intraperitoneal injection.
• Central apnea events during NREM and REM sleep were quantified and compared to control.

Main Results:

• R-zacopride significantly suppressed spontaneous central apneas in a dose-dependent manner during NREM sleep (50% reduction at 0.5 mg/kg, P=.05).
• All tested doses of R-zacopride reduced central apneas by 80% during REM sleep (P<.0007) for at least 2 hours.
• The compound demonstrated significant efficacy across a 20-fold dose range.

Conclusions:

• R-zacopride significantly reduces central apnea expression during both NREM and REM sleep in rats.
• The therapeutic effect is likely mediated by its 5-HT3 receptor antagonist or combined 5-HT4/5-HT3 receptor activity.
• R-zacopride represents a potential therapeutic agent for central sleep apnea.